Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru/Boston robotic digital pathology with RoboTome (2x sectioning speed) and MorphoLens (100+ slides/hour); $5M Series A Nov 2025 Inflexor Ventures with 80+ patents and US/European lab deployments competing with Leica for histopathology automation.
Morphle Labs is a Bengaluru, India and Boston, Massachusetts-based robotic microscopy and digital pathology company — raising $5 million in Series A funding in November 2025 led by Inflexor Ventures — providing histopathology laboratories with AI-powered physical automation platforms that address the speed and throughput bottlenecks in cancer diagnostics workflows. With 80+ patents filed and products deployed in leading US and European laboratories, Morphle's 100-member team has developed two flagship platforms: RoboTome (a robotic microtome system that slices biopsy tissue blocks at 2x the speed of experienced histotechnologists) and MorphoLens (a high-throughput slide scanner that digitizes 100+ histology slides per hour for digital pathology review). Founded to "revolutionize cancer diagnostics with physical AI," Morphle expands manufacturing, regulatory clearances, and global presence with the Series A.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.